Current therapeutical strategies in dementia;Aktuelle therapiemöglichkeiten der Alzheimer demenz

Neurologie und Rehabilitation

Volumn 9, Issue 1, 2003, Pages 15-22

  Faltraco, F ^a   Teipel, S J ^a   Moller H J ^a   Hampel, Harald ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidementive drugs; Behavioral symptoms; Pharmacological therapy

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DIHYDROERGOTOXINE; DIHYDROERGOTOXINE MESILATE; GINKGO BILOBA EXTRACT; LITHIUM; MELPERONE; MOCLOBEMIDE; NEUROLEPTIC AGENT; NICERGOLINE; NIMODIPINE; NOOTROPIC AGENT; OLANZAPINE; PIPAMPERONE; PIRACETAM; PROTHIPENDYL; PYRITINOL; RISPERIDONE; SELEGILINE; SERTINDOLE; SERTRALINE; TIAPRIDE; TRAZODONE; VALPROIC ACID; ZUCLOPENTHIXOL;

ALZHEIMER DISEASE; BEHAVIOR; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MENTAL DISEASE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TREATMENT PLANNING;

EID: 0038748096     PISSN: 09472177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Areosa Sastre A, Sherriff F: Memantine for dementia. The Cochrane Library, Issue 1 2003
2. Arzneimittelkommission der Deutschen Ärzteschaft: Empfehlungen zur Therapie der Demenz. Arzneiverordnung in der Praxis 1997; Sonderheft Therapieempfehlungen 4: 1-12
3. Baines S, Saxby P, Ehlert K. Reality orientation and reminescence therapy. A controlled cross-over study of elderly confused people. Br J Psychiatry 1987; 151: 222-231.
4. Bauer J: Die Alzheimer-Krankheit. Neurobiologie, Psychosomatik, Diagnostik und Therapie. Schattauer, Stuttgart 1994
5. Bhana N, Spencer CM: Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging 2000; 16: 451-471
6. Bickel H: Epidemiologie der Demenzen. Psycho 1995; 21: 716-722
7. Birge SJ: The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997; 48 (Suppl.7): 36-41
8. Cochrane Library, Issue 1 2003
9. Birks J, Grimley Evans J, Van Dongen M: Ginkgo Biloba for Cognitive Impairment and Dementia. The Cochrane Library, Issue 1 2003
10. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer's disease. The Cochrane Library, Issue 1 2003
11. Birks JS, Melzer D, Beppu H: Donepezil for mild and moderate Alzheimer's disease. In: The Cochrane Library, Issue 1 2003
12. Burke WJ, Dewan V, Wengel SP et al: The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry 1997; 12: 519-525
13. Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatric Psychopharmacology 1998; 1: 55-65
14. CPMP Working Party on Efficacy of Medical Products. Note for guidance. Antidementia medicinal products. Commission of the European Communities, Brussels, III/3705-91-EN. 1992; Draft 5
15. Croisile B, Trillet M, Fondarai J et al: Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993; 43: 301-305
16. Ehrhardt T, Kötter HU, Hampel H et al: Psychologische Therapieansätze bei Demenz. Zeitschrifi für Gerontopsychologie und Psychiatrie 1997; 10: 85-98
17. Farlow MR, Evans RM: Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 1998; 51(Suppl.1): S36-S44
18. Farlow M, Anand R, Messina J Jr, Hartmann R, Veach J. Eur Neurology 2000; 44 (4): 236-241
19. Fioravanti M, Flicker L: Efficacy of Nicergoline in dementia and other age associated forms of cognitive impairment. The Cochrane Library, Issue 1 2003
20. Fioravanti M, Yanagi M: Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. The Cochrane Library, Issue 1 2003
21. Flicker L, Grimley Evans J: Piracetam for dementia or cognitive impairment. The Cochrane Library, Issue 1 2003
22. Fox JM: Therapie mit antidementiellen Arzneimitteln und Nootropika. In: Fox M, Rüther E (Hrsg): Handbuch der Arzneimitteltherapie, Band I, Psychopharmaka, Thieme 1998
23. Goldberg RJ: The use of buspirone in geriatric patients. J Clin Psychiatry Monograph 1994; 12: 31-35
24. Growdon JH, Corkin S, Huff FJ et al: Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 1986; 7: 269-276
25. Hampel H, Padberg F, Kötter HU et al: Diagnostik und Therapie der Demenz vom Alzheimer-Typ. Münchner Medizinische Wochenschrift 1997; 139: 511-517
26. Hampel H, Padberg F, Möller HJ et al: Pharmakotherapie älterer Patienten mit dem selektiven MAO-A Inhibitor Moclobemid. Psychopharmakotherapie 1997; 4: 59-65
27. Hampel H, Padberg F, Möller HJ: Donepezil in der Pharmakotherapie der Alzheimer-Demenz. Psychopharmakotherapie 1998; 2: 54-61
28. Heiss WD, Kessler J, Mielke R: Long-term effects of phosphatidylserine, pyritinol and cognitive training in Alzheimer's disease. Dementia 1994; 5: 88-98
29. Herrschaft H: Piracetam. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka. Bd. 5: Parkinsonmittel und Nootropika. Springer-Verlag, Wien, 1992; 189-200
30. Hogervorst E, Yaffe K, Richards M, Huppert F: Hormone replacement therapy to maintain cognitive function in women with dementia. In: The Cochrane Library, Issue 1 2003
31. Kanowski S, Herrmann WM, Stephan K et al: Proof of efficacy of the Ginkgo Biloba Special Extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiat 1996; 29: 47-56
32. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a random double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-115
33. LeBars PL, Katz MM, Berman N et al: A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA 1997; 278: 1327-1332
34. Lebert F, Pasquier F, Petit H: Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry 1994; 55: 536-538
35. López-Arrieta, Birks J: Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). The Cochrane Library, Issue 1 2003
36. Lynch G, Kessler M, Rogers G et al: Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol 1996; 11: 13-19
37. Mackenzie IR, Munoz DG: Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998; 50: 986-990
38. Marx J: Searching for drugs that combat Alzheimer's. Science 1996; 273: 50-53
39. McKittrick LA, Camp JC, Black FW. Prospective memory intervention in Alzheimer's disease. J Gerontol 1992; 47: 337-343.
40. Meier D, Ermini-Fünfschilling D, Monsch AU et al: Kognitives Kompetenztraining mit Patienten im Anfangsstadium einer Demenz. Zeitschr Gerontopsychol 1996; 9: 207-217
41. Möller HJ: Beispiele klinischer Prüfmodelle für den Wirksamkeitsnachweis von Nootropika. In: Lungershausen E (Hrsg): Demenz. Herausforderung für Forschung, Medizin und Gesellschaft. Springer, Berlin, 1991; 147-157
42. Möller HJ: Tacrin, Möglichkeiten und Grenzen bei der Behandlung der Demenz vom Alzheimertyp. Psychopharmakotherapie 1996; 3: 103-108
43. Möller HJ: Therapie psychiatrischer Erkrankungen. 2., überarbeitete Ausgabe, Thieme, Stuttgart 2000
44. Müller WE, Mutschler E, Riederer P: Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiat 1995; 28: 113-124
45. Nappi G, Bono G, Merlo P et al: Long-term nicergoline treatment of mild to moderate senile dementia. Clin Drug Invest 1997; 13: 308-316
46. Nygaard HA, Bakke HK, Brudvik E, Elgen K, Lien GK: Dosing of neuroleptics in elderly demented patients with aggressive and agitated behaviour: a double-blind study with zuclopenthixol. Curr Med Res Opin 1994; 13: 222-232
47. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in the treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990; 157: 894-901
48. Olin J, Schneider L: Galantamine for Alzheimer's disease. The Cochrane Library, Issue 1 2003
49. Olin J, Schneider L, Novit A, Luczak S: Hydergine for dementia. The Cochrane Library, Issue 1 2003
50. Padberg F, Möller HJ, Stübner S, Boetsch T, Hampel H: Aktuelle Therapiemöglichkeiten der Alzheimer-Demenz. Die Medizinische Welt 1999; 50: 105-13
51. Reisberg B, Ferris SH, Sahin K, Windscheif U, Möbius HJ: Results of a placebo-controlled 6-month trial with memantine in moderate to severe Alzheimer's disease (AD). European Neuropsychopharmacology 2000; 10: 363
52. Rockwood K, Joffres C: Halifax Consensus Conference on Understanding the Effects of Dementia Treatment. Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations. Int J Geriatr Psychiatry 2002 Nov; 17 (11):1006-11
53. Rogers J, Kirby LC, Hempelman SR et al: Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993; 43: 1609-11
54. Sano M, Ernesto C, Thomas RG et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine 1997; 336: 1216-1222
55. Schneider LS, Olin JT: Overview of clinical trials of hydergine in dementia. Arch Neurol 1994; 51: 787-798
56. Schneider LS, Pollock VE, Lyness SA: A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia. JAGS 1990; 38: 553-563
57. Schneider LS, Sobin PB: Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review. Int. J Geriatr Psychiatry 1991; 6: 691-708
58. Statistisches Bundesamt: Statistisches Jahrbuch 1994 für die Bundes-republik Deutschland. Kohlhammer, Stuttgart, Mainz, 1994
59. Stewart WF, Kawas C, Corrada M et al: Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-632
60. Stoppe G, Brandt CA, Staedt JH: Behavioural problems associated with dementia: the role of new antipsychotics. Drugs Aging 1999; 14: 41-54
61. Sultzer DL, Gray KF, Gunay I, et al: A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5: 60-69
62. Tabet N, Birks J, Grimley Evans J, Orrel M, Spector A: Vitamin E for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 1 2003. Oxford: Update Software
63. Tabet N, Feldman H: Indomethacin for the treatment of Alzheimer's disease patients. In: The Cochrane Library, Issue 1 2003
64. Tang MX, Jacobs D, Stern Y et al: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432
65. Tariot PN, Erb R, Podgorski CA et al: Efficacy and Tolerability of Carbamazepine for Agitation ans Aggression in Dementia. Am J Psychiatry 1998; 155: 54-61
66. Winblad B, Poritis N: Memantine in severe dementia. Results of the M-Best Study. Int J Geriatr Psychiatry 1999; 14: 135-146
67. Yesavage JA, Westphal J, Rush L. Senile dementia: Combined pharmacologic and psychologic treatment. J Am Geriatr Soc 1981, 4: 164-171
68. Zanetti O, Frisoni GB, DeLeo D et al. Reality orientation therapy in Alzheimer Disease: Useful or not? A controlled study. Alzheimer Disease and Associated Disorders 1995; 9: 132-138.